CJC-1295 (no DAC) is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically a tetrasubstituted form of hGRF(1-29) with four amino acid substitutions that provide enhanced stability against enzymatic degradation, particularly by dipeptidyl peptidase-IV (DPP-IV). Unlike CJC-1295 with DAC, this version lacks the drug affinity complex (DAC) that binds to albumin, resulting in a shorter half-life but more pulsatile growth hormone release that mimics natural physiological patterns. The peptide works by binding to GHRH receptors on the anterior pituitary gland to stimulate growth hormone secretion.
30 minutes
Subcutaneous injection
0
CJC-1295 (no DAC) activates the GRF receptor on the anterior pituitary gland, stimulating the release of growth hormone (GH). The four amino acid substitutions (D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27) provide enhanced in vitro stability against DPP-IV degradation compared to native GHRH. In rat studies, subcutaneous administration demonstrated acute GH secretion with a 4-fold increase in GH area under the curve over a 2-hour period compared to unmodified hGRF(1-29).
Most clinical research on CJC-1295 was conducted on the DAC version. The no-DAC version (Modified GRF 1-29) shares the same active sequence but has shorter half-life. Human efficacy data is extrapolated from DAC studies.